Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal

Establishment of Precise Histological Evaluation Criteria for Reversal of NASH Fibrosis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.

Who May Be Eligible (Plain English)

Who May Qualify: - Aged between 18 and 70 years at the time of liver biopsy; - Gender is not limited; - Hepatic perforation suggested that NASH complicated with fibrosis stage F2-4; - Signed written willing to sign a consent form. Who Should NOT Join This Trial: - Combined HCV infection, HIV infection, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease Disease, drug-induced liver injury and other chronic liver diseases; - Women during pregnancy; - There are the following conditions before liver perforation: HCC or possible HCC (imaging suggests malignant liver occupation); decompensation of cirrhosis (ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, etc.); Patients with other malignant tumors; Recipients of liver transplantation; - Patients considered by the investigator to be unsuitable for this study. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Aged between 18 and 70 years at the time of liver biopsy; * Gender is not limited; * Hepatic perforation suggested that NASH complicated with fibrosis stage F2-4; * Signed written informed consent. Exclusion Criteria: * Combined HCV infection, HIV infection, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease Disease, drug-induced liver injury and other chronic liver diseases; * Women during pregnancy; * There are the following conditions before liver perforation: HCC or possible HCC (imaging suggests malignant liver occupation); decompensation of cirrhosis (ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, etc.); Patients with other malignant tumors; Recipients of liver transplantation; * Patients considered by the investigator to be unsuitable for this study.

Treatments Being Tested

OTHER

life-style

The patients were given health education and lifestyle intervention guidance, followed by lifestyle adjustment for at least 1 year and no more than 3 years, and a second liver biopsy was performed to evaluate liver histological changes.

Locations (1)

Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China